XenoGesis has been working with TropIQ and their Nijmegen-led collaboration on the generation of an innovative candidate drug against malaria.
A molecule that was once designed to cure the skin disease psoriasis has shown to be effective against malaria. The antimalarial properties were revealed thanks to a researcher’s inspired hunch when the psoriasis drug discovery programme came to a dead end. The candidate drug offers considerable potential for combatting the highly infectious malaria disease.
XenoGesis has been involved in this project and has worked with TropIQ on a number of projects over the last three years including supporting their research into vector-bone disease control.